GRC 27864

Drug Profile

GRC 27864

Latest Information Update: 18 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Analgesics; Anti-inflammatories; Antirheumatics
  • Mechanism of Action Prostaglandin-E synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain
  • Phase I Inflammation

Most Recent Events

  • 18 Jan 2018 GRC 27864 is still in phase I trials for Pain and Inflammation (In volunteers) in United Kingdom
  • 16 Jan 2018 Phase-II clinical trials in Pain in India (PO)
  • 16 Jan 2018 Directorate General of Health Services, Central Drugs Standard Control Organization (CDSCO), Government of India, approves a phase IIb trial for GRC 27864 in Pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top